Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32434790
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 J+Immunother+Cancer
2020 ; 8
(1
): ä Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
COVID-19 and immune checkpoint inhibitors: initial considerations
#MMPMID32434790
Sullivan RJ
; Johnson DB
; Rini BI
; Neilan TG
; Lovly CM
; Moslehi JJ
; Reynolds KL
J Immunother Cancer
2020[May]; 8
(1
): ä PMID32434790
show ga
COVID-19 infections are characterized by inflammation of the lungs and other
organs that ranges from mild and asymptomatic to fulminant and fatal. Patients
who are immunocompromised and those with cardiopulmonary comorbidities appear to
be particularly afflicted by this illness. During pandemic conditions, many
aspects of cancer care have been impacted. One important clinical question is how
to manage patients who need anticancer therapy, including immune checkpoint
inhibitors (ICIs) during these conditions. Herein, we consider diagnostic and
therapeutic implications of using ICI during this unprecedented period of
COVID-19 infections. In particular, we consider the impact of ICI on COVID-19
severity, decisions surrounding continuing or interrupting therapy, diagnostic
measures in patients with symptoms or manifestations potentially consistent with
either COVID-19 or ICI toxicity, and resumption of therapy in infected patients.
While more robust data are needed to guide clinicians on management of patients
with cancer who may be affected by COVID-19, we hope this commentary provides
useful insights for the clinical community.
|Antineoplastic Agents, Immunological/adverse effects/*therapeutic use
[MESH]